This study seeks to evaluate a multiparametric test including 6 immunohistochemical markers (PD-L1, CD8, FoxP3, PD1, CD163, CD15) to predict the cumulative incidence of death or progression on treatment with pembrolizumab+first line chemotherapy in metastatic non-small cell lung cancer, regardless of the PD-L1 status and in the absence of ALK, ROS1 or EGFR alteration.

Inclusion Criteria:

• 18 years at time of diagnosis
• Affiliation to a social insurance
• Obtaining the patient's non opposition
• Patients with non-small cell lung carcinoma, confirmed by anatomopathological, metastatic or locally advanced unresectable, not eligible for local curative treatment
• Cellular or tissue FFPE available
• Indication of treatment with pembrolizumab + first line chemotherapy in multidisciplinary consultation meeting
• No mutation of the EGFR gene, no rearrangement of ALK and ROS,
• At least one measurable tumor according to RECIST criteria

Exclusion Criteria:

• Tissue or cellular FFPE not available
• Systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or adjuvant treatment completed 6 months or more

Patients meeting the inclusion criteria will be selected in each of the centers (Lille CHU, Lille Centre Oscar Lambret, Valenciennes Clinique Teissier, Roubaix CH) by the onco-pneumologists and included in the study, after collecting the consent, at the start of treatment with pembrolizumab + chemotherapy in first line.